Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents

Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) catalyzes the final step in each elongation cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. High-throughput screening of the Staphylococcus aureus FabI enzyme identifie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Payne, David J., Miller, William H., Berry, Valerie, Brosky, John, Burgess, Walter J., Chen, Emile, DeWolf, Jr., Walter E., Fosberry, Andrew P., Greenwood, Rebecca, Head, Martha S., Heerding, Dirk A., Janson, Cheryl A., Jaworski, Deborah D., Keller, Paul M., Manley, Peter J., Moore, Terrance D., Newlander, Kenneth A., Pearson, Stewart, Polizzi, Brian J., Qiu, Xiayang, Rittenhouse, Stephen F., Slater-Radosti, Courtney, Salyers, Kevin L., Seefeld, Mark A., Smyth, Martin G., Takata, Dennis T., Uzinskas, Irene N., Vaidya, Kalindi, Wallis, Nicola G., Winram, Scott B., Yuan, Catherine C. K., Huffman, William F.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2002
Matèries:
Mechanisms of Action: Physiological Effects
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC128775/
https://ncbi.nlm.nih.gov/pubmed/12234833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.10.3118-3124.2002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars